Sterling Capital Management LLC Boosts Stake in Xencor, Inc. (NASDAQ:XNCR)

Sterling Capital Management LLC lifted its position in Xencor, Inc. (NASDAQ:XNCR) by 732.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,182 shares of the biopharmaceutical company’s stock after purchasing an additional 1,040 shares during the quarter. Sterling Capital Management LLC’s holdings in Xencor were worth $27,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 508 shares during the period. KBC Group NV raised its position in Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,337 shares during the period. Bank of Montreal Can purchased a new position in Xencor during the 4th quarter worth $239,000. Finally, Mutual of America Capital Management LLC acquired a new position in Xencor in the fourth quarter valued at $244,000.

Xencor Stock Down 3.0 %

XNCR opened at $10.51 on Friday. The business has a 50 day simple moving average of $11.77 and a 200-day simple moving average of $18.43. Xencor, Inc. has a 12 month low of $7.16 and a 12 month high of $27.24. The stock has a market capitalization of $740.56 million, a P/E ratio of -3.28 and a beta of 0.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, equities analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on XNCR shares. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. William Blair began coverage on Xencor in a research note on Monday, April 21st. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and an average target price of $33.86.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.